Skip to main navigation menu Skip to main content Skip to site footer
##common.pageHeaderLogo.altText##

Original article

Vol. 155 No. 1 (2025)

A cost-effectiveness analysis of sotorasib as second-line treatment for patients with KRAS-G12C-mutated metastatic non-small cell lung cancer (mNSCLC) in Switzerland

DOI
https://doi.org/10.57187/s.3777
Cite this as:
Swiss Med Wkly. 2025;155:3777
Published
06.01.2025

Summary

BACKGROUND AND OBJECTIVE: Because of the lack of effective targeted treatment options, docetaxel has long been the standard second-line therapy for patients with advanced non-small cell lung cancer, including the Kirsten rat sarcoma virus (KRAS) G12C mutation. The CodeBreak 200 trial demonstrated that sotorasib, a new drug targeting the G12C-mutated KRAS protein, modestly improved progression-free survival compared with docetaxel in patients whose cancer had progressed after receiving platinum chemotherapy and programmed cell death protein 1 (PD-1) / programmed death ligand 1 (PD-L1) inhibitors as first-line treatment. Consequently, sotorasib received temporary approval in Switzerland.

Our analysis assessed the cost-effectiveness of sotorasib as a second-line treatment in Swiss patients with non-small cell lung cancer from the perspective of the Swiss statutory health insurance system.

METHODS: A partitioned survival model based on the CodeBreak 200 trial was constructed with a time horizon of 10 years and a discount rate of 3% for costs and quality-adjusted life years (QALYs). Parametric survival curves were fitted to the published Kaplan-Meier data, and survival was extrapolated. QALYs were obtained from the CodeBreak 100 trial and the literature. The costs of drugs, drug administration, diagnostics, disease management, and adverse events were considered. Because the price of sotorasib has not been established in Switzerland, two scenarios were analysed: the first used the published expected monthly United Kingdom (UK) price in Swiss francs (CHF 7870); the second used one-quarter of that price (CHF 1968), according to the lower dose used in the most recent trial, under the condition that one-quarter of the original sotorasib dose is equally effective. Treatment costs of adverse events were included.

RESULTS: Log-normal functions best fitted the survival curves from CodeBreak 200. For sotorasib versus docetaxel, our estimation showed no difference in QALYs (1.28 QALYs for both treatments), as the reduced adverse events reported in CodeBreak 200 for sotorasib had a minimal impact on the QALYs in our calculation. This made an incremental cost-effectiveness ratio (ICER) calculation irrelevant. Total per-patient costs were CHF 138,894 for the full sotorasib dose, CHF 82,741 for the one-quarter dose, and CHF 80,383 for docetaxel. These results were robust in 99% of probabilistic simulations.

CONCLUSION: Sotorasib did not demonstrate cost-effectiveness at the full dosage nor when reduced to a quarter of the dose. The primary factors motivating clinicians to prescribe sotorasib are its superior overall response rate compared with docetaxel and the reported improvement in patients’ quality of life. These factors suggest that it would be reasonable to price it at approximately one-quarter of the assumed cost in the UK.

References

  1. WorldHealthOrganisation. International Agency for Research on Cancer. Cancer Today. 2023; Available from: https://gco.iarc.fr/today/online-analysis-pie?v=2020&mode=cancer&mode_population=continents&population=900&populations=756&key=total&sex=0&cancer=39&type=1&statistic=5&prevalence=0&population_group=0&ages_group%5B%5D=0&ages_group%5B%5D=17&nb_items=7&group_cancer=1&include_nmsc=1&include_nmsc_other=1&half_pie=0&donut=0#collapse-group-0-4
  2. Casal-Mouriño A, Ruano-Ravina A, Lorenzo-González M, Rodríguez-Martínez Á, Giraldo-Osorio A, Varela-Lema L, et al. Epidemiology of stage III lung cancer: frequency, diagnostic characteristics, and survival. Transl Lung Cancer Res. 2021 Jan;10(1):506–18. doi: https://doi.org/10.21037/tlcr.2020.03.40 DOI: https://doi.org/10.21037/tlcr.2020.03.40
  3. AmericanCancerSociety. What Is Lung Cancer? 2023; Available from: https://www.cancer.org/cancer/non-small-cell-lung-cancer/about/what-is-non-small-cell-lung-cancer.html
  4. Reita D, Pabst L, Pencreach E, Guérin E, Dano L, Rimelen V, et al. Direct Targeting KRAS Mutation in Non-Small Cell Lung Cancer: focus on Resistance. Cancers (Basel). 2022 Mar;14(5):1321. doi: https://doi.org/10.3390/cancers14051321 DOI: https://doi.org/10.3390/cancers14051321
  5. Mullard A, Cracking KR. Cracking KRAS. Nat Rev Drug Discov. 2019 Nov;18(12):887–91. doi: https://doi.org/10.1038/d41573-019-00195-5 DOI: https://doi.org/10.1038/d41573-019-00195-5
  6. Hendriks LE, Kerr KM, Menis J, Mok TS, Nestle U, Passaro A, et al.; ESMO Guidelines Committee. Electronic address: clinicalguidelines@esmo.org. Non-oncogene-addicted metastatic non-small-cell lung cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann Oncol. 2023 Apr;34(4):358–76. doi: https://doi.org/10.1016/j.annonc.2022.12.013 DOI: https://doi.org/10.1016/j.annonc.2022.12.013
  7. de Langen AJ, Johnson ML, Mazieres J, Dingemans AC, Mountzios G, Pless M, et al.; CodeBreaK 200 Investigators. Sotorasib versus docetaxel for previously treated non-small-cell lung cancer with KRASG12C mutation: a randomised, open-label, phase 3 trial. Lancet. 2023 Mar;401(10378):733–46. doi: https://doi.org/10.1016/S0140-6736(23)00221-0 DOI: https://doi.org/10.1016/S0140-6736(23)00221-0
  8. FDA. FDA Approves First Targeted Therapy for Lung Cancer Mutation Previously Considered Resistant to Drug Therapy 2021; Available from: https://www.fda.gov/news-events/press-announcements/fda-approves-first-targeted-therapy-lung-cancer-mutation-previously-considered-resistant-drug
  9. Hochmair, M.J., et al., VP4. Sotorasib 960 mg versus 240 mg in pretreated KRAS G12C advanced NSCLC. Ann Oncol. 2023.
  10. Popat S. SOTORASIB 960MG VERSUS 240MG IN PRETREATED KRAS G12C ADVANCED NSCLCIs less, more? ESMO Virtual Plenary; 2023.
  11. Arbour KC; Preliminary Clinical Activity of RMC-6236, a First-in-Class, RAS-Selective, Tri-Complex RASMULTI(ON) Inhibitor in Patients with KRAS-Mutant Pancreatic Ductal Adenocarcinoma (PDAC) and Non-Small Cell Lung Cancer (NSCLC). 2023, ESMO Congress 2023. DOI: https://doi.org/10.1016/j.annonc.2023.09.1838
  12. Swissmedic. Lumykras® (active substance: sotorasib). 2022; Available from: https://www.swissmedic.ch/swissmedic/en/home/about-us/publications/public-summary-swiss-par/public-summary-swiss-par-lumykras.html
  13. Versicherungsärzte SG. Nutzenbewertung zur Vergütung von Arzneimitteln im Einzelfall (Art. 71a - 71d KVV). 2023; Available from: https://www.vertrauensaerzte.ch/expertcom/71kvv/updmay18/
  14. RCoreTeam. R: A language and environment for statistical computing. Vienna, Austria: R Foundation for Statistical Computing; 2021.
  15. TreeAgePro. 2021, R1. TreeAge Software, Williamstown, MA.
  16. Husereau D, Drummond M, Augustovski F, de Bekker-Grob E, Briggs AH, Carswell C, et al.; CHEERS 2022 ISPOR Good Research Practices Task Force. Consolidated Health Economic Evaluation Reporting Standards 2022 (CHEERS 2022) Statement: Updated Reporting Guidance for Health Economic Evaluations. Value Health. 2022 Jan;25(1):3–9. doi: https://doi.org/10.1016/j.jval.2021.11.1351 DOI: https://doi.org/10.1016/j.jval.2021.11.1351
  17. Shepherd FA, Dancey J, Ramlau R, Mattson K, Gralla R, O’Rourke M, et al. Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy. J Clin Oncol. 2000 May;18(10):2095–103. doi: https://doi.org/10.1200/JCO.2000.18.10.2095 DOI: https://doi.org/10.1200/JCO.2000.18.10.2095
  18. Anderson H, Hopwood P, Stephens RJ, Thatcher N, Cottier B, Nicholson M, et al. Gemcitabine plus best supportive care (BSC) vs BSC in inoperable non-small cell lung cancer—a randomized trial with quality of life as the primary outcome. UK NSCLC Gemcitabine Group. Non-Small Cell Lung Cancer. Br J Cancer. 2000 Aug;83(4):447–53. doi: https://doi.org/10.1054/bjoc.2000.1307 DOI: https://doi.org/10.1054/bjoc.2000.1307
  19. Guyot P, Ades AE, Ouwens MJ, Welton NJ. Enhanced secondary analysis of survival data: reconstructing the data from published Kaplan-Meier survival curves. BMC Med Res Methodol. 2012 Feb;12(1):9. doi: https://doi.org/10.1186/1471-2288-12-9 DOI: https://doi.org/10.1186/1471-2288-12-9
  20. Christopher Jackson, P.M., Jordan Amdahl, Matthew T. Warkentin, Michael Sweeting, Kevin Kunzmann, flexsurv: Flexible Parametric Survival and Multi-State Models. 2023.
  21. statistics, S.E.A.i.w.f.S.c. Surveillance Research Program, National Cancer Institute; 2023 Apr 19. 2023; Available from: https://seer.cancer.gov/statistics-network/explorer/
  22. BAG. B.f.G. Spezialitätenliste. Available from: https://www.spezialitätenliste.ch/.
  23. Tarmed FM. Available from: https://browser.tartools.ch/de/tarmed_kvg
  24. FederalStatisticalOffice. HVPI Schweiz (2015=100), Totalindex und 12 Hauptgruppen, Veränderungsraten Totalindex. 2023; Available from: https://www.bfs.admin.ch/bfs/en/home/statistics/catalogues-databases/tables.assetdetail.24405716.html
  25. Bundesamt für Gesundheit BAG. Preisfestsetzung von Arzneimitteln: Auslandpreisvergleich und therapeutischer Quervergleich. 2015; Available from: https://www.bag.admin.ch/dam/bag/de/dokumente/kuv-leistungen/KUV-abgeschlossene%20Revisionen%20(Themen%20&%20Service)/Arzneimittel/29.%20April%202015/faktenblatt-auslandpreisvergleich-und-therapeutischer-quervergleich.pdf.download.pdf/faktenblatt-auslandpreisvergleich-und-therapeutischer-quervergleich.pdf
  26. NICE. Sotorasib for previously treated KRAS G12C mutation-positive advanced non-small-cell lung cancer. 2022; Available from: https://www.nice.org.uk/guidance/ta781/documents/final-appraisal-determination-document-2
  27. FederalStatisticalOffice. Durchschnittliche Körpergrösse (in cm). 2023; Available from: https://www.bfs.admin.ch/bfs/en/home/statistics/catalogues-databases.assetdetail.7586022.html
  28. EXCELLENCE. N.I.F.H.A.C. Sotorasib for previously treated KRAS G12C mutated, locally advanced or metastatic non-small-cell lung cancer [ID3780]. [Single Technology Appraisal] 2021 30th June 2021; Available from: https://www.nice.org.uk/guidance/ta781/evidence/committee-papers-pdf-11014968349
  29. NICE. Pembrolizumab for treating PD-L1-positive non-small-cell lung cancer after platinum-based chemotherapy [ID840]. 2016. Available from: https://www.nice.org.uk/guidance/ta428/documents/committee-papers
  30. Nafees B, Stafford M, Gavriel S, Bhalla S, Watkins J. Health state utilities for non small cell lung cancer. Health Qual Life Outcomes. 2008 Oct;6(1):84. doi: https://doi.org/10.1186/1477-7525-6-84 DOI: https://doi.org/10.1186/1477-7525-6-84
  31. Rothwell B, Kiff C, Ling C, Brodtkorb TH. Cost Effectiveness of Nivolumab in Patients with Advanced, Previously Treated Squamous and Non-squamous Non-small-cell Lung Cancer in England. PharmacoEconom Open. 2021 Jun;5(2):251–60. doi: https://doi.org/10.1007/s41669-020-00245-4 DOI: https://doi.org/10.1007/s41669-020-00245-4
  32. Hong DS, Fakih MG, Strickler JH, Desai J, Durm GA, Shapiro GI, et al. KRASG12C Inhibition with Sotorasib in Advanced Solid Tumors. N Engl J Med. 2020 Sep;383(13):1207–17. doi: https://doi.org/10.1056/NEJMoa1917239 DOI: https://doi.org/10.1056/NEJMoa1917239
  33. Skoulidis F, Li BT, Dy GK, Price TJ, Falchook GS, Wolf J, et al. Sotorasib for Lung Cancers with KRAS p.G12C Mutation. N Engl J Med. 2021 Jun;384(25):2371–81. doi: https://doi.org/10.1056/NEJMoa2103695 DOI: https://doi.org/10.1056/NEJMoa2103695
  34. vonMoos R. Was darf eine Krebstherapie kosten? Schweiz Arzteztg. 2021;102(3132):1007–9. DOI: https://doi.org/10.4414/saez.2021.19840
  35. Paracha N, Abdulla A, MacGilchrist KS. Systematic review of health state utility values in metastatic non-small cell lung cancer with a focus on previously treated patients. Health Qual Life Outcomes. 2018 Sep;16(1):179. doi: https://doi.org/10.1186/s12955-018-0994-8 DOI: https://doi.org/10.1186/s12955-018-0994-8
  36. Mok TS, Lawler WE, Shum MK, Dakhil SR, Spira AI, Barlesi F, et al. KRYSTAL-12: A randomized phase 3 study of adagrasib (MRTX849) versus docetaxel in patients (pts) with previously treated non-small-cell lung cancer (NSCLC) with KRASG12C mutation. J Clin Oncol. 2021;39(15 suppl):TPS9129–9129. doi: https://doi.org/10.1200/JCO.2021.39.15_suppl.TPS9129 DOI: https://doi.org/10.1200/JCO.2021.39.15_suppl.TPS9129
  37. Mullard A. The KRAS crowd targets its next cancer mutations. Nat Rev Drug Discov. 2023 Mar;22(3):167–71. doi: https://doi.org/10.1038/d41573-023-00015-x DOI: https://doi.org/10.1038/d41573-023-00015-x
  38. Waterhouse D, et al. Patient-reported outcomes from the CodeBreaK 200 phase 3 trial comparing sotorasib versus docetaxel in KRAS G12C-mutated NSCLC. European Lung Cancer Congress 2023, 2023. DOI: https://doi.org/10.1016/S1556-0864(23)00258-7
  39. Matter-Walstra K, Schwenkglenks M, Aebi S, Dedes K, Diebold J, Pietrini M, et al.; Swiss Group for Clinical Cancer Research. A Cost-Effectiveness Analysis of Nivolumab versus Docetaxel for Advanced Nonsquamous NSCLC Including PD-L1 Testing. J Thorac Oncol. 2016 Nov;11(11):1846–55. doi: https://doi.org/10.1016/j.jtho.2016.05.032 DOI: https://doi.org/10.1016/j.jtho.2016.05.032
  40. Barbier MC, Pardo E, Panje CM, Gautschi O, Lupatsch JE; Swiss Group for Clinical Cancer Research (SAKK). A cost-effectiveness analysis of pembrolizumab with or without chemotherapy for the treatment of patients with metastatic, non-squamous non-small cell lung cancer and high PD-L1 expression in Switzerland. Eur J Health Econ. 2021 Jul;22(5):669–77. doi: https://doi.org/10.1007/s10198-021-01282-4 DOI: https://doi.org/10.1007/s10198-021-01282-4
  41. Lippi G, Mattiuzzi C, Montagnana M. BRCA population screening for predicting breast cancer: for or against? Ann Transl Med. 2017 Jul;5(13):275. doi: https://doi.org/10.21037/atm.2017.06.71 DOI: https://doi.org/10.21037/atm.2017.06.71
  42. Gamble C, Havrilesky LJ, Myers ER, Chino JP, Hollenbeck S, Plichta JK, et al. Cost Effectiveness of Risk-Reducing Mastectomy versus Surveillance in BRCA Mutation Carriers with a History of Ovarian Cancer. Ann Surg Oncol. 2017 Oct;24(11):3116–23. doi: https://doi.org/10.1245/s10434-017-5995-z DOI: https://doi.org/10.1245/s10434-017-5995-z
  43. statistics, S.E.A.i.w.f.S.c. Adenocarcinoma of the Lung and Bronchus. SEER Relative Survival Rates by Time Since Diagnosis, 2000-2019. 2023; Available from: https://seer.cancer.gov/statistics-network/explorer/application.html?site=612&data_type=4&graph_type=6&compareBy=stage&chk_stage_106=106&sex=1&race=1&age_range=1&advopt_precision=1&advopt_show_ci=on&advopt_show_count=on&hdn_view=0&advopt_show_apc=on&advopt_display=2#resultsRegion0
  44. Panje CM, Dedes KJ, Matter-Walstra K, Schwenkglenks M, Gautschi O, Siano M, et al.; Swiss Group for Clinical Cancer Research (SAKK). A cost-effectiveness analysis of consolidative local therapy in oligometastatic non-squamous non-small cell lung cancer (NSCLC). Radiother Oncol. 2018 Nov;129(2):257–63. doi: https://doi.org/10.1016/j.radonc.2018.07.017 DOI: https://doi.org/10.1016/j.radonc.2018.07.017
  45. Matter-Walstra KW, Achermann R, Rapold R, Klingbiel D, Bordoni A, Dehler S, et al. Delivery of health care at the end of life in cancer patients of four swiss cantons: a retrospective database study (SAKK 89/09). BMC Cancer. 2014 May;14(1):306. doi: https://doi.org/10.1186/1471-2407-14-306 DOI: https://doi.org/10.1186/1471-2407-14-306

Most read articles by the same author(s)

1 2 > >>